| 1.3 -0.005 (-0.38%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.91  |
1-year : | 2.2 |
| Resists | First : | 1.64 |
Second : | 1.88 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.25 |
Second : | 1.03 |
| MAs | MA(5) : | 1.34 |
MA(20) : | 1.51 |
| MA(100) : | 1.15 |
MA(250) : | 0.99 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 4.6 |
| RSI | RSI(14): 44.3 | |||
| 52-week | High : | 1.88 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MYO ] has closed above bottom band by 18.9%. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.33 | 1.33 - 1.34 |
| Low: | 1.23 - 1.24 | 1.24 - 1.25 |
| Close: | 1.29 - 1.3 | 1.3 - 1.31 |
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Fri, 11 Sep 2026
Myomo (NYSE: MYO) insider to sell 15,844 shares after two recent sales - Stock Titan
Wed, 02 Sep 2026
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference - BioSpace
Mon, 31 Aug 2026
Myomo Leads The Pack Of 3 Promising Penny Stocks - simplywall.st
Thu, 20 Aug 2026
Myomo (NYSE: MYO) officer eyes 17,500-share stock sale - Stock Titan
Wed, 05 Aug 2026
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 25 Jun 2026
MYO Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|